ucart123
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 19, 2017 (NCT03190278)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ucart123
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04106076 | Phase 1 | Jul 11, 2019 | Cellectis S.A., University of London |
| NCT03203369 | Phase 1 | Jun 28, 2017 | Cellectis S.A. |
| NCT03190278 | Phase 1 | Jun 19, 2017 | Cellectis S.A. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cellectis S.A. | For profit | 3 | 3 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1